米托蒽醌治疗晚期膀胱癌。欧洲癌症研究与治疗组织泌尿生殖系统癌症合作组的一项II期研究。
Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group.
作者信息
van Oosterom A T, Fosså S D, Mulder J H, Calciati A, de Pauw M, Sylvester R
出版信息
Eur J Cancer Clin Oncol. 1985 Sep;21(9):1013-4. doi: 10.1016/0277-5379(85)90284-6.
PMID:4065174
Abstract
Mitoxantrone at a dose of 12 mg/m2 i.v. q 3 weeks failed to produce a response in 28 adequately treated patients with measurable advanced bladder cancer. The side-effects observed in this group of patients with a good performance status were generally mild. On the basis of this negative result the use of mitoxantrone in this disease cannot be recommended.
摘要
对于28例接受过充分治疗的可测量晚期膀胱癌患者，采用剂量为12mg/m²静脉注射、每3周一次的米托蒽醌治疗未产生反应。在这组身体状况良好的患者中观察到的副作用通常较轻。基于这一阴性结果，不建议在该疾病中使用米托蒽醌。
Zotero 插件